




This research training curriculum is a collaborative project aimed at making the science of HIV cure-related research accessible to the community and the HIV research field.



Module Outline

- Key timeline events
- Research process overview
- Research 'dam' analogy
- Stem cell transplantations
- Early ART

CUREiculum

- Draining the 'reservoir'
- Reinforcing the 'dam'
- Making cells stronger
- Putting different strategies together






Key timeline events









HIV cure is rare.

5

324

60

÷

Ĥ

49

52

A

0

Ĥ

0

ŧŋ


0

Ĥ

🏶 CUREiculum

HIV Cure is Rare: Elimination and Durable ART-Free Suppression

2009



5

674 1

60

-

Ð

Ê

13

5

C

ĥ

0

to

Ĥ




Overview of the Research Process










Why is HIV so hard to cure?



5

60

Ð

.

Ĥ

13

5

C

ĥ

0

ທ

<u>د</u>


So few cells harbor HIV in people on antivirals medications and these cells appear normal to our immune system CUREiculum



Research 'dam' analogy








How Can We Prevent HIV From Rebounding Off Therapy?

CUREiculum



SLIDE CREDIT: Jones RB. The Newest Science in Cure and Vaccine. Plenary Presentation Main IAS 2018 Conference. **U**

4

60

13

H

40

5

0

ĥ

3

S

Щ

Strategies Towards HIV Cure

Latency reversal- reactivate latent HIV with drugs and kill with immune system

Gene therapy to **delete HIV** out of cells

Gene therapy to make cells resistant to HIV

Vaccines / Immunotherapies – enhance immune responses to control virus




CUREiculum

Block and lock' – permanently silence HIV expression (force into deeper latency)



R. Brad Jones

HIV Cure-Related Research Strategies Under Investigation



5

9 - 1

60

-

Ð

.

Ĥ

13

5


Ċ.

E4

3

to

Ĥ



Stem Cell Transplantations



CUREiculum

Timothy Ray Brown "The Berlin Patient" March 11, 1966 - September 29, 2020

years

months

|3

Donor: CCR5 Δ32 homozygous **Recipient:** CCR5 \triangle 32 heterozygous Acute myelogenous leukemia

Two stem cell transplants

Total body irradiation full intensity conditioning T cell depletion with ATG

Mild GVHD* / 100% chimerism

5 years



Adam Castillejo "The London Patient"

Donor: CCR5 ∆32 homozygous **Recipient: CCR5** Wild Type

Hodgkins lymphoma

One stem cell transplant

No irradiation reduced intensity conditioning T cell depletion with aCD52

Mild GVHD* / 100% chimerism

******GVHD = Graft Vs. Host Disease

Timing of ART Initiation Following HIV Infection

Very early ART

Effects of early ART

Reduced immune activation Limited virus escape/diversity Reduced morbidity and mortality

Better c<mark>ontro</mark>l on ART

No seroc<mark>onver</mark>sion, lack of adaptive immune responses

Smaller reservoirs Preserved immunity


CUREiculum

Chronic ART Early ART

Fiebig I/II (1-3 wks p.i.)<48 hours</td>< 6 months</td>

> 6 months - years

Caroline Tiemesser











Draining the 'reservoir'











- KEYE WIV sneaks Immune System a System of cells, tissues and organs within the body that helpfight off infections adiverses. hide away HIV successfully infiltrates the cell and makes itself at home in the cell DNA CAPTAIN LRA HAS COME TO SAVE THE DAY!!! HIV (Human Immunodeficiency Views) A virus that enters the body and attacks cells that help the body to fighe off infections, making the body highly susceptible to distances and infections.



5

60

Ð

Ĥ

ψ

5

0

F

08

0

ίΩ

Ĥ




(ell is



Visual Art Credit: Eric (Yi-Hao) Lee, Jasmin Guzman, and Matylda McCormack-Sharp

5 -60 Ð Ĥ 4 52 Ø **F** 0 ίΩ Ĥ





LOCATED

HIV DNA

Once I've located

HIV in a cell

sale -





÷KEY€

Immune System

(Includes CD4 T lymphocyte cells) A System of cells, tissues and organs within the body that help fight off infections and diseases



(Auman Immunodeticiency Virus) A virus that enters and attacks

the cells that help to fight off infections, making the body highly susceptible to diseases and infections

DNA 🖁

Genetic material found in all living organisms that contains the main constituent of chromo somes. It is self-multiplying and contains all genetic info

5 60 1) H 40 5 0 **F** 08 0 **m** Ĥ


🏶 CUREiculum











Latently-Infected Cell 🚳

A cell that is affected by the HIV but not actively producing the virus. It's hard for the immune system cell to recognize it as an affected cell because of its inactivity.

Block and Lock Strategy

A strategy that targets and silences the HIV virus DNA in the latently-infected cell. The cell can return to its normal activity but the viral DNA stays silent.



Story by: Eric Lee, Matylda Mai & Jazmin Guzman (Pencils) (Inksklettering) (colors)



Center for AIDS Prevention Studies Division of Prevention Sciences

Visual Art Credit: Eric (Yi-Hao) Lee, Jasmin Guzman, and Matylda McCormack-Sharp








Reinforcing the 'dam'







The Immune Response

B CELL

T CELL

B cells make antibodies that target specific pathogens

T cells kill pathogens and

attack infected cells

INFECTED ADAPTIVE CELL RESPONSE

athogens

INNATE Signaling MMUNE molecules RESPONSE

INNATE IMMUNE CELLS

Innate immune cells engulf and kill pathogens and release molecules to enhance the immune response Some T and B cells become memory cells that quickly fight future infections by the same pathogen

IMMEDIATE RESPONSE

🗮 CUREiculum

DELAYED RESPONSE

Bucher

Types of HIV Therapeutic Vaccines

5

60

-

13

4

10

5


0


E4

3

S

Щ





5

.

-

60

.

40

Ĥ

ψ

5

0

F

0

ίΩ

Ĥ





Story by Eric Lee, Matylda Mai & Jazmin Guzman (Pencils) (Inks) (colors)

Y4C

Visual Art Credit: Eric (Yi-Hao) Lee, Jasmin Guzman, and Matylda McCormack-Sharp




Passive Immunization:

bNAb can potently inhibit HIV

Isolate broadly

neutralizing antibodies



CUREiculum



5

60

Ð

4

Ð

5

C

F

Genetic Engineered T cells: Creating Super T Cells

Chimeric Antigen Receptor (CAR) T cells



CUREiculum

CD8+ T cells

HIV envelope

HIV-infected cell

with surface expression of

Single chain variable fragments derived from bNAbs

CAR-T cell therapy in virally suppressed people on ART (China; NCT03240328)


Modified from a slide by Dr. Thor Wagner (U Washington) Hale and Wagner, Mol Ther 2017; Ali, J Virol 2016; Liu, J Virol 2016; Hale, Mol Ther 2017

SLIDE CREDIT: Ananworanich, A. Overview of Ongoing Cure Research Globally. Community Cure Workshop. Saturday July 21, 2018.



Making cells stronger





What is Cell and Gene Modification?

A branch of Regenerative Medicine, an emerging field that involves the "process of replacing, engineering or regenerating human cells, tissues or organs to restore or establish normal function". 5

60

Ð

H

40

5

0

E4

.


0

ທ

<u>L</u>

- Gene therapy is the delivery of therapeutic gene into a patient's cells to treat disease.
- Cell therapy is the delivery of intact, living cells into a patient to treat disease.
- Combination Cell/Gene Modification approaches that seek to insert genes into a patients' own cells to control or kill HIV are in clinical trials now.

🏶 CUREiculum



Cell and Gene Modification



X

🏶 CUREiculum



Modification Occurring Outside the Body 'Ex Vivo'

Ex vivo gene therapy

A

CUREiculum

Isolation of desired cell types from the patient, followed by gene modification and reinfusion Outside of the body



Collect cells from patient Isolate T cell from leukapheresis or stem cell from bone marrow **Gene modification** See gene modification strategy panel below Expansion Expansion of gene-edited cells **Re-infuse** Put the modified cells back into the patient

> Illustration Credit: Grace Hsu, MS, CMI, Scientific Animation, Animation Lab: https://animationlab.utah.edu/

Modification Occurring Inside the Body 'In Vivo' (C) Inside of the body

In vivo gene therapy

8


CUREiculum

Vectors or nanoparticles are used to carry anti-HIV genes to the target cells *in situ*

Adenovirus Lentivirus

Vectors

See gene modification strategy panel below



5

60

Ð

Ĥ

13

5

0

ĥ


.

ίΩ

Ĥ



IMMUNOTEAM: DEFEND N ASSIST



÷KEY€

Immune System (Includes CONT lymphocyte cells) A system of cells, tissues and organs within the body that help fight off infections and diseases



HIV 💥

(Aman Immunedeficiency Virus) A virus that enters and attacks the cells that help to fight off infections, making the body highly susceptible to diseases and infections

DNA 8

Genetic material found in all living organisms that contains the main constituent of chromo somes. It is self-multiplying and contains all genetic info

Gene Editing There are two main forms :

 Cells are taken out of the body to have some of their genetic characteristics modified.
Genes in the cells are modified. 5

60



🗮 CUREiculum

After their training, they are taken back to teach and assist the other cells how to find, protect and defend against HIV.



while they are still inside the body.

Goal: To make specific cells resistant to or better at Fighting HW,or to change the HIV itself so it becomes ineffective.

Gene Direct Approach

To make the immune system better at locating and fighting HIV

To make immune cells resistant to HIV entry

Story by: Eric Lee, Matylda Mai & Jazmin Guzman (Pencils) (Inksklettering) (colors)



Center for AIDS Prevention Studies Division of Prevention Sciences

> Visual Art Credit: Eric (Yi-Hao) Lee, Jasmin Guzman, and Matylda McCormack-Sharp

Treatment Action Group Research Towards an HIV Cure (Trials)

TAG

CUREiculum

Research Toward a Cure June 15, 2021

Table 1. Current Clinical Trials

Trial	Trial Registry Identifier(s)	Sponsor(s)	Phase	Estimated End Date/Interim Results
ADOPTIVE IMMUNOTHERAPY				
alloRESIST: Evaluate the safety, immunologic, and virologic responses of donor derived HIV-specific T- cells in HIV+ individuals following allogeneic bone marrow transplantation	NCT04248192	Catherine Bollard, Children's Research Institute	Phase I	April 2024
HST-NEETS: HIV-1 specific T-cells for HIV-infected individuals	NCT03485963	Children's Research Institute	Phase I	December 2021
ANTIBODIES				
VRC01 (analytical treatment interruption in HVTN 703/HPTN 081 AMP trial participants)	NCT04860323	HIV Vaccine Trials Network	N/A	November 2022
VRC01 (analytical treatment interruption in HVTN 704/HPTN 085 AMP trial participants)	NCT04801758	HIV Vaccine Trials Network	N/A	June 2022
GSK3810109A (broadly neutralizing antibody formerly named N6-LS)	NCT04871113 (not yet open for enrollment)	ViiV Healthcare	Phase IIa	October 2023
10-1074-LS + 3BNC117-LS in primary HIV infection	NCT04319367 (not yet open for enrollment)	Imperial College London	Phase II	March 2025


• List of trials and pipeline report



Putting different strategies together










Questions for Discussion





PACKNOWLEDGMENTS



CUREiculum














Module developers

Richard Jefferys TAG Danielle Campbell DARE CAB Christopher Roebuck BEAT-HIV CAB **Michael Louella** defeatHIV CAB Karine Dubé UNC Chapel Hill

Illustrators:

Eric (Yi-Hao) Lee Jasmin Guzman Matylda McCormack-Sharp

Grace Hsu, Animation Lab

Biomedical Co-Leads

Professor Sharon Lewin, Doherty Institute David R Kuritzkes, MD, Brigham and Women's Hospital Jintanat Ananworanich, Bill and Melinda Gates Research Institute

We wish to thank AIDS Treatment Activists Coalition for the funding to complete this module

Their caring support of the CUREiculum 2.0. will make a difference in the lives of thousands. of people living with HIV

